Join the Nexletol group to help and get support from people like you.
Nexletol News
U.S. FDA Approves Broad New Labels for Nexletol and Nexlizet to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
ANN ARBOR, Mich., March 22, 2024 (GLOBE NEWSWIRE) – Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for...
U.S. FDA Updates LDL-C Lowering Indication for Esperion’s Nexletol (bempedoic acid) Tablet and Nexlizet (bempedoic acid and ezetimibe) Tablet
Updated Label Adds Primary Hyperlipidemia, Removes Maximally Tolerated Statin Requirement, Removes Limitation of Use Cardiovascular (CV) Risk Reduction Labels Remain on Track: in U.S. with PDUFA...
American Diabetes Association, June 23-26
The annual meeting of the American Diabetes Association was held this year from June 23 to 26 in San Diego and attracted more than 15,000 participants from around the world, including clinicians,...
FDA Approves Nexletol (bempedoic acid) to Lower LDL-Cholesterol
ANN ARBOR, Mich., Feb. 21, 2020 (GLOBE NEWSWIRE) – Esperion (NASDAQ:ESPR) announced today that the U.S. Food and Drug Administration (FDA) approved Nexletol™ (bempedoic acid) tablet, an oral, o...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Cardiovascular Risk Reduction, High Cholesterol - Familial Heterozygous, High Cholesterol